The 5th Annual Gene Therapy for Rare Disorders Europe is dedicated to overcoming manufacturing, clinical, and commercialisation challenges drug developers face when delivering gene therapies to market.

In the context of unprecedented clinical activity, rapidly approaching approvals and investment at an all-time high, Gene Therapy for Rare Disorders Europe will leverage the experience from the first to market pioneers, as well as unveiling the strategies the next generation of drug developers are employing to improve the efficacy, safety and commercial viability of your gene therapy pipeline.

Across three content-packed days, this conference will unite leading experts from innovative biotechs, large pharma, academia and key service provider companies, all with the specific focus of solving complex commercial challenges to deliver on the promise of gene therapies for rare disease patients.

Wherever you’re based, if you’re looking to develop and launch gene therapy products in Europe, this is your comprehensive guide to define your commercial path forward.

Access the full event guide here for more information.

World-Class Speaking Faculty

Christina Ohnsman

Senior Clinical Development Lead


Craig Martin

Chief Executive Officer

Global Genes

Mike Fraser

General Manager Europe, Middle East and Africa

Novartis Gene Therapies

Nicholas Medcalf

ISCF Deputy Challenge Director, Medicines Manufacturing

Innovate UK

Angela Columbano

Head, Business Development & Partnership


Anne Douar

Chief Development Officer

Vivet Therapeutics

Magali Taiel

Chief Medical Officer

GenSight Biologics

Paolo Morgese

EU Director Market Access & Member Relations

Alliance for Regenerative Medicine (ARM)

Other Events in the Gene Therapy Series

Proud to Partner With:

Thermo Fisher Scientific (003)
Primary Logo Light Background (002)